A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

ClinicalTrials.gov ID: NCT06975722

Public ClinicalTrials.gov record NCT06975722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 12, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Study identification

NCT ID: NCT06975722
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Sanofi; Industry
Enrollment: 99 participants

Conditions and interventions

Conditions

Ulcerative Colitis

Interventions

SAR442970 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 6, 2025
Primary completion: Dec 16, 2026
Completion: Oct 16, 2029
Last update posted: Apr 22, 2026

2025 – 2029

United States locations

U.S. sites: 21
U.S. states: 12
U.S. cities: 20

Facility	City	State	ZIP	Site status
Investigational Site Number: 8400009	Escondido	California	92025	Recruiting
Investigational Site Number: 8400006	Lancaster	California	93534	Recruiting
Investigational Site Number: 8400025	Thousand Oaks	California	91360	Recruiting
Investigational Site Number: 8400024	Jacksonville	Florida	32258	Recruiting
Investigational Site Number: 8400030	Kissimmee	Florida	347441	Recruiting
Investigational Site Number: 8400003	Lighthouse PT	Florida	33064	Recruiting
Investigational Site Number: 8400001	Miami	Florida	33134	Recruiting
Investigational Site Number: 8400011	Miami	Florida	33136	Recruiting
Investigational Site Number: 8400010	Palmetto Bay	Florida	33176	Recruiting
Investigational Site Number: 8400019	Tampa	Florida	33609	Recruiting
Investigational Site Number: 8400018	Marietta	Georgia	30060	Recruiting
Investigational Site Number: 8400005	Iowa City	Iowa	52242	Recruiting
Investigational Site Number: 8400017	Boston	Massachusetts	02115	Recruiting
Investigational Site Number: 8400012	Wyoming	Michigan	49519	Recruiting
Investigational Site Number: 8400014	St Louis	Missouri	63110	Recruiting
Investigational Site Number: 8400021	New York	New York	10029	Recruiting
Investigational Site Number: 8400029	Queens Village	New York	11428	Recruiting
Investigational Site Number: 8400002	Chapel Hill	North Carolina	27514	Recruiting
Investigational Site Number: 8400013	Harrisburg	Pennsylvania	17110	Recruiting
Investigational Site Number: 8400023	Houston	Texas	77030	Recruiting
Investigational Site Number: 8400007	Ogden	Utah	84405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06975722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 22, 2026 · Synced Sep 12, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06975722 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →